Related Experiment Video
Updated: Dec 28, 2025
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells
Rajesha Rupaimoole1, Bohyung Yoon1, Wen Cai Zhang1
1HMS Initiative for RNA Medicine and Department of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Abstract:
MicroRNA-34 (miR-34) is one of the major families of tumor suppressor miRNAs often lost in cancers. Delivery of miR-34a mimics to affected tumors as a therapeutic strategy has been tried in pre-clinical studies and in a phase I clinical trial. One approach to increase efficacy and reduce toxicity is to rationally identify drug combinations with small molecules that synergize with miR-34a. In this study we performed a high-throughput screen of a large panel of small molecules with known biological activity and identified ouabain as a candidate small molecule that synergized with miR-34a in killing lung cancer cells. We elucidated autophagy activation as a key mechanism by which miR-34a and ouabain causes increased cytotoxicity in cells. We posit that this combinatorial approach could reduce the active dose of miR-34a needed in vivo to observe tumor shrinkage and potentiate the development of miR-34a combination therapies in the future.
Insights
Combining microRNA-34a (miR-34a) therapy with ouabain shows promise for lung cancer treatment. This combination activates autophagy, increasing cancer cell death and potentially reducing therapeutic doses.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- MicroRNA-34 (miR-34) family acts as tumor suppressors, frequently lost in various cancers.
- miR-34a mimic delivery is explored as a cancer therapeutic strategy, with pre-clinical and early clinical trials underway.
- Enhancing miR-34a efficacy and reducing toxicity necessitates identifying synergistic drug combinations.
Purpose of the Study:
- To identify small molecules that synergize with miR-34a to enhance cancer cell killing.
- To elucidate the underlying mechanism of synergy between miR-34a and identified small molecules.
- To explore the potential of this combination therapy for future lung cancer treatment.
Main Methods:
- High-throughput screening of a large panel of small molecules with known biological activity.
- Assessment of synergistic effects of miR-34a mimics and candidate small molecules on lung cancer cell lines.
- Elucidation of the cellular mechanisms, including autophagy activation, involved in the combined treatment's cytotoxicity.
Main Results:
- Ouabain was identified as a small molecule that synergizes with miR-34a in killing lung cancer cells.
- Autophagy activation was identified as a key mechanism mediating the increased cytotoxicity of the miR-34a and ouabain combination.
- The combination therapy demonstrated enhanced cell death in lung cancer cells.
Conclusions:
- The combination of miR-34a mimics and ouabain exhibits synergistic anti-cancer activity in lung cancer cells.
- Autophagy activation is a critical pathway through which this combination exerts its cytotoxic effects.
- This combinatorial approach may allow for reduced miR-34a dosage in vivo, potentially leading to tumor shrinkage and advancing miR-34a-based combination therapies.
